Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)

Journal of Clinical Oncology

Volumn 35, Issue 35, 2017, Pages 3924-3933

  Horn, Leora ^a   Spigel, David R ^b   Vokes, Everett E ^c   Holgado, Esther ^d   Ready, Neal ^g   Steins, Martin ^h   Poddubskaya, Elena ^l   Borghaei, Hossein ^m   Felip, Enriqueta ^e   Paz Ares, Luis ^f   Pluzanski, Adam ⁿ   Reckamp, Karen L ^o   Burgio, Marco A ^p   Kohlhäeufl, Martin ⁱ   Waterhouse, David ^q   Barlesi, Fabrice ^r   Antonia, Scott ^t   Arrieta, Oscar ^u   Fayette, Jérôme ^s   Crinò, Lucio ^p   Rizvi, Naiyer ^v   Reck, Martin ^j   Hellmann, Matthew D ^v   Geese, William J ^w   Li, Ang ^w   Blackwood Chirchir, Anne ^w   Healey, Diane ^w   Brahmer, Julie ^x   Eberhardt, Wilfried E E ^k   more..

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Hospital de Madrid   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ ROBERT BOSCH HOSPITAL   (Germany)

^j GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^k RUHRLANDKLINIK   (Germany)

^l N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^m FOX CHASE CANCER CENTER   (United States)

ⁿ INSTITUTE OF ONCOLOGY   (Poland)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^p DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^q Oncology Hematology Care   (United States)

^r AIX MARSEILLE UNIVERSITY   (France)

^s CENTRE LÉON BÉRARD   (France)

^t H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^u INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^v MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^w BRISTOL MYERS SQUIBB   (United States)

^x JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; DOCETAXEL; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK REDUCTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; CONTROLLED STUDY; KAPLAN MEIER METHOD; LUNG TUMOR; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 85037986316     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.3062     Document Type: Article

References (22)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. American Cancer Society: Non-small cell lung cancer. https://www.cancer.org/cancer/non-small-celllung-cancer.html
3. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264, 2012
4. Melosky B, Chu Q, Juergens R, et al: Pointed progress in second-line advanced non-small-cell lung cancer: The rapidly evolving field of checkpoint inhibition. J Clin Oncol 34:1676-1688, 2016
5. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer. N Engl J Med 373:123-135, 2015
6. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627-1639, 2015
7. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
8. Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015
9. Ferris RL, Blumenschein G Jr, Fayette J, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856-1867, 2016
10. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015
11. Younes A, Santoro A, Shipp M, et al: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, singlearm phase 2 trial. Lancet Oncol 17:1283-1294, 2016
12. Opdivo [package insert]. Bristol-Myers Squibb, Princeton, NJ. 2017
13. Opdivo [summary of product characteristics]. Bristol-Myers Squibb, Uxbridge, United Kingdom. 2017
14. Brahmer J, Horn L, Jackman DM, et al: Fiveyear follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer: Clinical characteristics of long-term survivors. American Association for Cancer Research Annual Meeting, Washington, DC, 2017 [abstr CT077]
15. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
16. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, NCCN Evidence Blocks: non-small cell lung cancer version 4.2017, 2017.
17. Novello S, Barlesi F, Califano R, et al: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v1-v27, 2016 (suppl 5)
18. Weber JS, Postow M, Lao CD, et al: Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21:1230-1240, 2016
19. Keytruda [package insert]. Merck Sharp & Dohme Corp, Whitehouse Station, NJ. 2016
20. Tecentriq [package insert]. Genentech, San Francisco, CA. 2016
21. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
22. Rittmeyer A, Barlesi F, Waterkamp D, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255-265, 2017